Eledon Pharmaceuticals (FRA:2TK) YoY EBITDA Growth : 35.44% (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Eledon Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 35.44%.

Eledon Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was €-0.22.

Eledon Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Eledon Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals YoY EBITDA Growth Chart

Eledon Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

52.82

75.84

-18.90

39.02

13.04

Eledon Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															53.75	19.04	4.32	-7.35	35.44

Eledon Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Eledon Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-1.381	-	-1.588)	/	\| -1.588 \|
=	13.04 %

Eledon Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-0.215	-	-0.333)	/	\| -0.333 \|
=	35.44 %

Eledon Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

ELDN:USA 2TK:Germany

Address

19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612

Website

https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals Headlines

No Headlines